High-dose-rate interstitial brachytherapy for accelerated partial breast irradiation – trial results of Azerbaijan National Center of Oncology

• Main Authors: Jamil A. Aliyev, Isa H. Isayev, Kamal S. Akbarov, Samir S. Qurbanov, Ruslan R. Huseynov, Nigar S. Aliyeva
• Format: Article
• Language: English
• Published: Termedia Publishing House 2017-04-01
• Series: Journal of Contemporary Brachytherapy
• Subjects: APBI; breast cancer; intermediate risk; interstitial brachytherapy
• Online Access: https://www.termedia.pl/High-dose-rate-interstitial-brachytherapy-for-accelerated-partial-breast-irradiation-trial-results-of-Azerbaijan-National-Center-of-Oncology,54,29812,1,1.html

Purpose : To describe early results of two cohorts of patients with low and intermediate risk of early breast cancer treated with accelerated partial breast irradiation (APBI) using different schedules of multicatheter brachytherapy. Material and methods: Patients with early stage breast cancer after breast conserving surgery were enrolled for a prospective analysis. The APBI, using multicatheter brachytherapy, was delivered either eight times 4 Gy in five days with a planned total dose of 32 Gy, or seven times 5 Gy in four days with a planned total dose of 35 Gy. Primary endpoints were side effects. Results : Forty-eight patients were enrolled between 2012 and 2014. Patients characteristics were as follow: median age of patients was 55 years, early breast cancer was defined according GEC-ESTRO recommendations. With a median follow-up period of 37 months, no significant differences regarding late side effects and cosmesis between two cohorts of patients were documented. In total, cosmesis was excellent in 13/48 (27.1%) patients, good in 34/48 (70.8%) patients, and moderate in 1/48 patient (2.1%). Conclusions : Accelerated partial breast irradiation using multicatheter brachytherapy with 32 Gy/8 fractions and 35 Gy/7 fractions for early breast cancer seems to be similar in terms of late side effects. According to our findings, APBI was also feasible for intermediate-risk of early breast cancer patients.